Clinical Trial Update: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) [Phase 2]

View source ↗

Summary

A Phase 2 study of MK-3655 for pre-cirrhotic Nonalcoholic Steatohepatitis was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• MK-3655

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: TERMINATED | Results posted: 2024-04-29